EGFR-mutation-positive non-small-cell lung cancer (3rd-gen TKI).
Osimertinib
Brand reference: Tagrisso (AstraZeneca, India)
View medicine detailsBrowse the complete current list by molecule or brand name. A catalogue source reference does not identify the dispensing pharmacy or country, and a listing does not confirm availability.
28 medicines listed
EGFR-mutation-positive non-small-cell lung cancer (3rd-gen TKI).
Brand reference: Tagrisso (AstraZeneca, India)
View medicine details
Metastatic prostate cancer (CYP17 inhibitor).
Brand reference: Zytiga (Janssen, India)
View medicine details
Advanced prostate cancer (androgen-receptor inhibitor).
Brand reference: Bdenza
View medicine detailsStrength40 mg
HR+/HER2- advanced breast cancer (CDK4/6 inhibitor).
Brand reference: Palnat
View medicine details
HR+/HER2- advanced breast cancer (CDK4/6 inhibitor).
Brand reference: Kryxana (Novartis, India)
View medicine detailsStrength200 mg
BRCA-mutated ovarian, breast, pancreatic and prostate cancers (PARP inhibitor).
Brand reference: Bracanat
View medicine details
Multiple myeloma and certain haematological cancers.
Brand reference: Lenalid
View medicine details
Chronic myeloid leukaemia and GIST (tyrosine kinase inhibitor).
Brand reference: Imatib
View medicine details
Breast, colorectal and gastric cancers (oral chemotherapy).
Brand reference: Capegard
View medicine details
EGFR-mutation-positive non-small-cell lung cancer (first-generation TKI).
Brand reference: Geftinat
View medicine detailsStrength250 mg
Multiple myeloma.
Brand reference: Pomide
View medicine details
Chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia.
Brand reference: Dasanat
View medicine details
Brain tumours, including selected gliomas.
Brand reference: Temonat
View medicine details
Renal cell carcinoma, gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.
Brand reference: Sunitinib
View medicine details
Renal cell carcinoma and soft-tissue sarcoma.
Brand reference: Pazopanib
View medicine details
Selected breast, renal cell and neuroendocrine tumours.
Brand reference: Evermil
View medicine details
HR-positive, HER2-negative breast cancer.
Brand reference: Ramiven
View medicine details
Chronic lymphocytic leukaemia and acute myeloid leukaemia.
Brand reference: Venetoclax
View medicine details
Chronic lymphocytic leukaemia, mantle-cell lymphoma and related blood cancers.
Brand reference: Ibrutinib
View medicine details
Hormone-sensitive breast cancer.
Brand reference: Letrozole
View medicine detailsStrength2.5 mg
Hormone-sensitive breast cancer.
Brand reference: Anazol
View medicine detailsStrength1 mg
Renal cell, liver and thyroid cancers.
Brand reference: Sorafenib
View medicine detailsStrength200 mg
Thyroid cancer and selected renal cell or liver cancer regimens.
Brand reference: Lenvatinib
View medicine details
EGFR-positive non-small-cell lung cancer and selected pancreatic cancer treatment.
Brand reference: Erlocip
View medicine details
HER2-positive breast cancer.
Brand reference: Lapatinib
View medicine detailsStrength250 mg
Breast cancer.
Brand reference: Tamoxifen
View medicine details
Colorectal cancer, gastrointestinal stromal tumours and liver cancer.
Brand reference: Regorafenib
View medicine detailsStrength40 mg
Myelofibrosis and selected haematological conditions.
Brand reference: Ruxolitinib
View medicine detailsThe active ingredient is often printed in smaller type below the brand name. A caregiver can search either name.